How to Handle Pro Rata and Board Seat Requests in Your Seed Round

You've got a term sheet. The investor wants pro rata rights and maybe a board seat. What do you do? I'm going to walk you through exactly how to think about these requests, as a medical startup founder who needs to protect your runway, your clinical timeline, and your future fundraising leverage.

This article is for educational purposes only and is not financial advice, not legal advice, and not tax advice. Figures vary; consult a qualified professional before making decisions.

Are pro rata rights and board seats standard in a seed round?

Short answer: they're negotiable, not automatic. Whether you see them in your seed round depends almost entirely on who's writing the check, how much they're putting in, and how badly you need the money.

Pro rata rights are simply the contractual right to invest in future rounds so the investor can maintain their percentage ownership. For example, if Investor A buys 10% in your seed, a pro rata right lets them buy more later when you raise a Series A to keep that 10% from diluting.

A board seat is something else entirely, a real seat at the table, with voting power, fiduciary duties, and the ability to influence everything from hiring to strategy. Early-stage medical startups should be especially deliberate here. The regulatory path is long, clinical validation is noisy, the burn rate is high, and reimbursement assumptions can flip overnight. The last thing you need is an outsider with a board seat slowing you down or pushing you in the wrong direction.

Board observer rights are a lighter touch, the investor can attend meetings and see the materials, but can't vote. That's almost always the smarter starting point.

Medical startups face extra scrutiny from investors precisely because of those built-in delays and regulatory uncertainties. A cardiology device company might need 18 months just to get an IDE approved before a single patient is enrolled. That changes the risk profile. The term sheet that works for a SaaS company often flops for a medtech or digital health play. You need terms that reflect your real-world timeline, not the average startup's.

How to decide whether to grant pro rata rights

Pro rata rights can make sense. But you should grant them surgically, not as a blanket "yes."

When pro rata rights work well: you've landed a high-quality lead investor, someone with deep healthcare connections, a track record of follow-on support, and the ability to carry signaling weight into your Series A. That investor is essentially anchoring your future raise. Giving them full pro rata (or something close to it) can help you lock in that commitment. Strategic investors who bring distribution channels, clinical partnerships, or payer relationships also earn the right to be taken seriously here.

The downside is that if too many seed investors hold pro rata rights, the entire next round can get eaten up before you've even met a new lead. I've seen seed-stage cap tables with five or six pro rata holders. When the Series A target is only $5 M, and $3 M of it is already spoken for, new institutional VCs walk away. Don't crowd them out.

Here's the decision framework I use:

• Company stage and capital need: If you're pre-revenue and still finishing clinical validation, preserve flexibility. If you're already generating revenue or have strong proof-of-concept data, you can be slightly more generous.
• Expected next round size: If it's a modest raise, limit pro rata. If you'll need a large round ($10 M+), you have more room.
• Investor quality: Is this a name that top-tier Series A funds respect? If not, a pro rata right can actually hurt you when those later funds see a weak signal.
• Your leverage: In a competitive oversubscribed round, you hold the cards. Investors will accept less. In a tougher raise, you trade rights for a commitment.

My strong recommendation: grant pro rata only to investors above a certain check size, say, the lead and any who wrote a check of at least $250 k in a $2 M round. Or keep it for the lead only. And always cap it as a percentage of the next round (e.g., "up to $500 k"). That keeps the door open for new blood.

How to think about board seats in a seed round

Board seats are not participation trophies. They're governance tools, and they should almost always be reserved for a lead investor or a founder-friendly independent you bring in later, not a seed investor who wrote a $100 k check.

Here's the hierarchy of control, from least to most intrusive:

1. Information rights: the investor gets quarterly financials and updates, nothing more.
2. Advisory role: a seat on your advisory board with no formal authority.
3. Board observer: attendance at board meetings, no vote, no fiduciary obligations to the company.
4. Board seat: full voting member of the board of directors, with duties to shareholders. This is a major concession.

Medical startups can't afford governance gridlock. You're balancing regulatory submissions, key opinion leader relationships, prototyping, CRO management, and safety monitoring. A board director who doesn't understand FDA logic or who insists on changing the clinical endpoint to boost valuation can wreck months of work. I've watched a neuro device startup lose six months because an investor director demanded an unnecessary pilot study, right before a PMA submission, purely out of unfamiliarity with the regulatory pathway. Don't let that happen.

Red flags: an investor who asks for a board seat without putting up lead economics (20%+ of the round). Or one who wants veto power over hiring the CMO or clinical trial design. Or who insists on a board larger than three people at seed. A three-person board, two founders, one lead investor, is the sweet spot. Even then, make sure the board can move fast.

Negotiation tactics and sample term-sheet guardrails

Investors will push. You'll push back. Here's the language and structure that works.

Pro rata guardrails:

• Pro rata right limited to the lead investor only.
• Pro rata right capped at a maximum dollar amount (not a percentage of the new round) to prevent ballooning.
• Pro rata right expires if the investor fails to invest their pro rata amount in X consecutive rounds.
• Pro rata right subject to a minimum ownership threshold (e.g., must still own >2% after the next round to participate).

Board and governance guardrails:

• Offer a board observer seat instead of a director role, especially to smaller or earlier-stage investors.
• If a board seat is unavoidable, tie it to a lead investment of at least $X and require that director to step down if the investor sells below a certain ownership level.
• Carve out founder-only control over specific decisions: clinical protocol design, principal investigator selection, regulatory strategy, and key hires. A "founder veto" on those matters is perfectly reasonable at seed.
• Include a clear "no veto" provision in the term sheet: no investor will have blocking rights over future financings, exits, or board expansion without supermajority consent.

These aren't just legal formalities. They protect your ability to move fast. Your charter, voting agreement, and board resolutions need to mirror these guardrails. That's where counsel comes in. I can't stress this enough: don't let the term sheet say one thing and the definitive docs say another. I've seen founders inadvertently give up board control through a voting agreement they didn't fully parse. Your lawyer should map every governance term back to your operating reality.

When you're in the room, prioritize like this:

1. Protect founder control over clinical and hiring decisions.
2. Preserve flexibility for the next round.
3. Only trade governance for true strategic value, not just money.

If an investor pushes for an onerous board seat, I often say, "We're building a board that can move at the speed of regulatory timelines. Here's what we can offer instead: observer rights, plus a standing advisory committee call once a quarter." That works more often than you'd think.

A practical checklist for closing the seed round

Before you sign, walk through this:

• Investor identity and size of rights clearly match the lead vs. non-lead dynamic.
• Board composition is minimal, ideally three people, and you control the founder seats.
• Observer language is explicit: observer may attend but not vote, and you have the right to exclude them from sensitive topics (like clinical endpoint discussions).
• No side letters undermine the term sheet. If an investor asks for something extra, it goes into the main set of documents, not a hidden addendum.

For medical startups specifically:

• Protect your IP ownership and assignment clauses, no investor should have an equity trigger that claims IP developed separately.
• Align clinical milestones with the financing needed to hit them; don't let a governance structure slow you down if the science demands a pivot.
• Avoid any right of first refusal on regulatory pathways or partnering deals that could tie your hands.

Final litmus test: Ask yourself, "Does this term help my company raise the next round and build the product faster, without adding unnecessary friction?" If the answer is no, negotiate it out.

Use this article as a negotiation checklist. But it's not a substitute for legal counsel. Get a startup-savvy healthcare attorney to review every document before you sign.

Key Takeaways

• Pro rata rights are common, but they should be granted selectively, not automatically, in a seed round.
• A board seat is much more consequential than an observer right, so founders should treat it as a major governance tradeoff.
• Medical startups need to preserve flexibility because regulatory, clinical, and financing needs can change quickly.